Ann: Cyclopharm Signs First USA Contract for Technegas, page-8

What I do find interesting is that you are basing your conclusions of direct comparison. When I look at the 2 different companies, I see two different beasts. Granted if you are just being selective by way of a few meterics, you would be correct! However IMO failing to take other intangibles into your assumptions of value ignore the reality of the current market. Companies need to promote their success and brand to a wide audience, or get stuck in the "purist" category. I can think of innovative medtech companies like RHT, CMP or even MX1 that to me, are viewed by the wider market as "purist" ie; succeeding in the science but failing to "sell" their story. Its early days in the 4DX and CYC penetration into the US markets, however so far 4DX is winning by telling their story. And when people listen, they talk, and tell others. This "intangible value" cannot be overstated in the current market.

You may not choose to see the market that way, and that's ok. It's not to say the company won't be successful. However, like any busy market, the loudest guy promoting his cheap goods is going to attract more customers than the quiet trader in the corner. And that in turn builds demand, which then adds a "premium" compared to their peers.